Review

ctip2 cells (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech ctip2 cells

(A,D,G) Representative images of control, continuous Imp1 overexpression, and T1 Imp1 conditions showing TEMPO reporters, <t>Cux1/Ctip2</t> immunostaining and overlays. Boxed regions: Ctip2+ TEMPO neurons (dashed) or double-positive Cux1+/Ctip2+ TEMPO cells (solid). (B,E,H) High magnification images of boxed regions highlight CFP-/RFP-labeled neurons in layers V-VI colocalizing with Ctip2 (outlined arrowheads) or double-positive for both markers (solid arrowheads). (C,F,I) Quantification of marker expression in CFP+ and RFP+ neurons residing in layers V-VI. Following continuous or T1 Imp1 overexpression, neurons in deep layer maintain appropriate deep-layer molecular identities (predominantly Ctip2+), demonstrating that laminar distribution reflects bona fide fate specification changes rather than mislocalization. (C) In control conditions, CFP+: Ctip2 (78.31% ± 13.82%), Cux1 (2.93% ± 2.11%), double-negative (18.76% ± 11.73%). RFP+: Ctip2 (50.35% ± 17.01%), Cux1 (1.85% ± 1.85%), double-negative (46.76% ± 17.20%), double-positive (1.04% ± 1.04%). (F) Following continuous Imp1 overexpression, CFP+: Ctip2+ (71.18% ± 3.06%), Cux1+ (7.38% ± 4.93%), double-negative (16.06% ± 1.93%), double-positive (5.38% ± 1.80%). RFP+: Ctip2+ (58.92% ± 7.18%), Cux1+ (5.84% ± 3.01%), double-negative (5.10% ± 3.12%), double-positive (30.14% ± 11.98%). (I) In T1 Imp1 overexpression, CFP+: Ctip2+ (47.26% ± 4.88%), Cux1+ (14.63% ± 3.76%), double-negative (36.41% ± 5.64%), double-positive (1.68% ± 0.57%). RFP+: Ctip2+ (47.38% ± 13.91%), Cux1+ (9.17% ± 4.68%), double-negative (26.86% ± 5.03%), double-positive (16.59% ± 10.02%). Dashed lines: upper (II-IV), lower cortical layers (V-VI) and subplate zone (SPZ). Scale bars: (A,D,G) 100 µm and (B,E,H) 20 µm. Data show mean±SEM. Statistics: two-tailed unpaired Welch’s t-test (*P < 0.05, **P < 0.01, *** P < 0.001).

Ctip2 Cells, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctip2 cells/product/Proteintech
Average 93 stars, based on 14 article reviews

ctip2 cells - by Bioz Stars, 2026-05

93/100 stars

Images

1) Product Images from "Imp1 acts as a dosage- and stage-dependent temporal rheostat orchestrating radial glial fate transitions and cortical morphogenesis"

Article Title: Imp1 acts as a dosage- and stage-dependent temporal rheostat orchestrating radial glial fate transitions and cortical morphogenesis

Journal: bioRxiv

doi: 10.1101/2025.11.18.688993

(A,D,G) Representative images of control, continuous Imp1 overexpression, and T1 Imp1 conditions showing TEMPO reporters, Cux1/Ctip2 immunostaining and overlays. Boxed regions: Ctip2+ TEMPO neurons (dashed) or double-positive Cux1+/Ctip2+ TEMPO cells (solid). (B,E,H) High magnification images of boxed regions highlight CFP-/RFP-labeled neurons in layers V-VI colocalizing with Ctip2 (outlined arrowheads) or double-positive for both markers (solid arrowheads). (C,F,I) Quantification of marker expression in CFP+ and RFP+ neurons residing in layers V-VI. Following continuous or T1 Imp1 overexpression, neurons in deep layer maintain appropriate deep-layer molecular identities (predominantly Ctip2+), demonstrating that laminar distribution reflects bona fide fate specification changes rather than mislocalization. (C) In control conditions, CFP+: Ctip2 (78.31% ± 13.82%), Cux1 (2.93% ± 2.11%), double-negative (18.76% ± 11.73%). RFP+: Ctip2 (50.35% ± 17.01%), Cux1 (1.85% ± 1.85%), double-negative (46.76% ± 17.20%), double-positive (1.04% ± 1.04%). (F) Following continuous Imp1 overexpression, CFP+: Ctip2+ (71.18% ± 3.06%), Cux1+ (7.38% ± 4.93%), double-negative (16.06% ± 1.93%), double-positive (5.38% ± 1.80%). RFP+: Ctip2+ (58.92% ± 7.18%), Cux1+ (5.84% ± 3.01%), double-negative (5.10% ± 3.12%), double-positive (30.14% ± 11.98%). (I) In T1 Imp1 overexpression, CFP+: Ctip2+ (47.26% ± 4.88%), Cux1+ (14.63% ± 3.76%), double-negative (36.41% ± 5.64%), double-positive (1.68% ± 0.57%). RFP+: Ctip2+ (47.38% ± 13.91%), Cux1+ (9.17% ± 4.68%), double-negative (26.86% ± 5.03%), double-positive (16.59% ± 10.02%). Dashed lines: upper (II-IV), lower cortical layers (V-VI) and subplate zone (SPZ). Scale bars: (A,D,G) 100 µm and (B,E,H) 20 µm. Data show mean±SEM. Statistics: two-tailed unpaired Welch’s t-test (*P < 0.05, **P < 0.01, *** P < 0.001).

Figure Legend Snippet: (A,D,G) Representative images of control, continuous Imp1 overexpression, and T1 Imp1 conditions showing TEMPO reporters, Cux1/Ctip2 immunostaining and overlays. Boxed regions: Ctip2+ TEMPO neurons (dashed) or double-positive Cux1+/Ctip2+ TEMPO cells (solid). (B,E,H) High magnification images of boxed regions highlight CFP-/RFP-labeled neurons in layers V-VI colocalizing with Ctip2 (outlined arrowheads) or double-positive for both markers (solid arrowheads). (C,F,I) Quantification of marker expression in CFP+ and RFP+ neurons residing in layers V-VI. Following continuous or T1 Imp1 overexpression, neurons in deep layer maintain appropriate deep-layer molecular identities (predominantly Ctip2+), demonstrating that laminar distribution reflects bona fide fate specification changes rather than mislocalization. (C) In control conditions, CFP+: Ctip2 (78.31% ± 13.82%), Cux1 (2.93% ± 2.11%), double-negative (18.76% ± 11.73%). RFP+: Ctip2 (50.35% ± 17.01%), Cux1 (1.85% ± 1.85%), double-negative (46.76% ± 17.20%), double-positive (1.04% ± 1.04%). (F) Following continuous Imp1 overexpression, CFP+: Ctip2+ (71.18% ± 3.06%), Cux1+ (7.38% ± 4.93%), double-negative (16.06% ± 1.93%), double-positive (5.38% ± 1.80%). RFP+: Ctip2+ (58.92% ± 7.18%), Cux1+ (5.84% ± 3.01%), double-negative (5.10% ± 3.12%), double-positive (30.14% ± 11.98%). (I) In T1 Imp1 overexpression, CFP+: Ctip2+ (47.26% ± 4.88%), Cux1+ (14.63% ± 3.76%), double-negative (36.41% ± 5.64%), double-positive (1.68% ± 0.57%). RFP+: Ctip2+ (47.38% ± 13.91%), Cux1+ (9.17% ± 4.68%), double-negative (26.86% ± 5.03%), double-positive (16.59% ± 10.02%). Dashed lines: upper (II-IV), lower cortical layers (V-VI) and subplate zone (SPZ). Scale bars: (A,D,G) 100 µm and (B,E,H) 20 µm. Data show mean±SEM. Statistics: two-tailed unpaired Welch’s t-test (*P < 0.05, **P < 0.01, *** P < 0.001).

Techniques Used: Control, Over Expression, Immunostaining, Labeling, Marker, Expressing, Two Tailed Test

Image Search Results

Erythropoietin (EPO) effects on neuron number, proliferation and apoptosis in CA1 and CA3. All data are based on bilateral counting. ( a ) Experimental design of the in vivo experiments (see f for age at treatment in the magnetic resonance imaging (MRI) design). Mice received EPO or placebo intraperitoneally (i.p.) every other day, starting on postnatal day 28. ( b ) Number of pyramidal neurons in CA1 and CA3 at 1 week after 3-week EPO versus placebo treatment (w4) (analysis was performed in two independent experiments with identical results; n =17 in CA1 for both groups, and n =16 and n =18 in CA3 for placebo and EPO, respectively). ( c ) Sample cresyl violet staining, illustrating that pyramidal neurons (arrowhead) can be clearly distinguished from other cells (arrow). ( d ) Number of CTIP2+ pyramidal neurons in CA1 at w4 ( n =4 per group). ( e ) Illustration of the CTIP2 staining in the dorsal hippocampus. The white rectangle indicates the magnified area shown in the lower right corner. ( f ) MRI-based volumetrical analysis of whole hippocampus (HC) after EPO or placebo ( n =6 per group; treatment in this set of male mice was initiated at 11 weeks of age; that is, MRI data were obtained at age 15 weeks). ( g ) Proliferation determined by 5'-bromo-deoxyuridine (BrdU) incorporation at w4 (placebo n =7 and EPO n =6). ( h ) Apoptotic cells analyzed with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (Tunel) staining at w4 ( n =10 for both groups). ( i ) Confocal analysis of BrdU and NeuN double-positive cells at w4 ( n =6 for both groups). ( j ) Confocal picture showing a neuron staining positively for NeuN (green) and BrdU (red). ( k and l ) Number of Pax6-positive cells at 72h and w1 ( n =9 per group). ( m ) Pax6+ cells (arrows) visualized by 3,3'-diaminobenzidine (DAB) staining. ( n ) Number of doublecortin (Dcx)-positive cells at w4 ( n =9 per group). ( o ) Sample picture of Dcx+ cells. All bar graphs shown as mean±s.e.m.; all analyses unpaired, two-tailed t -tests; * P <0.05, ** P <0.01, *** P <0.001, **** P <0.0001.

Journal: Molecular Psychiatry

Article Title: Revisiting adult neurogenesis and the role of erythropoietin for neuronal and oligodendroglial differentiation in the hippocampus

doi: 10.1038/mp.2015.212

Figure Lengend Snippet: Erythropoietin (EPO) effects on neuron number, proliferation and apoptosis in CA1 and CA3. All data are based on bilateral counting. ( a ) Experimental design of the in vivo experiments (see f for age at treatment in the magnetic resonance imaging (MRI) design). Mice received EPO or placebo intraperitoneally (i.p.) every other day, starting on postnatal day 28. ( b ) Number of pyramidal neurons in CA1 and CA3 at 1 week after 3-week EPO versus placebo treatment (w4) (analysis was performed in two independent experiments with identical results; n =17 in CA1 for both groups, and n =16 and n =18 in CA3 for placebo and EPO, respectively). ( c ) Sample cresyl violet staining, illustrating that pyramidal neurons (arrowhead) can be clearly distinguished from other cells (arrow). ( d ) Number of CTIP2+ pyramidal neurons in CA1 at w4 ( n =4 per group). ( e ) Illustration of the CTIP2 staining in the dorsal hippocampus. The white rectangle indicates the magnified area shown in the lower right corner. ( f ) MRI-based volumetrical analysis of whole hippocampus (HC) after EPO or placebo ( n =6 per group; treatment in this set of male mice was initiated at 11 weeks of age; that is, MRI data were obtained at age 15 weeks). ( g ) Proliferation determined by 5'-bromo-deoxyuridine (BrdU) incorporation at w4 (placebo n =7 and EPO n =6). ( h ) Apoptotic cells analyzed with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (Tunel) staining at w4 ( n =10 for both groups). ( i ) Confocal analysis of BrdU and NeuN double-positive cells at w4 ( n =6 for both groups). ( j ) Confocal picture showing a neuron staining positively for NeuN (green) and BrdU (red). ( k and l ) Number of Pax6-positive cells at 72h and w1 ( n =9 per group). ( m ) Pax6+ cells (arrows) visualized by 3,3'-diaminobenzidine (DAB) staining. ( n ) Number of doublecortin (Dcx)-positive cells at w4 ( n =9 per group). ( o ) Sample picture of Dcx+ cells. All bar graphs shown as mean±s.e.m.; all analyses unpaired, two-tailed t -tests; * P <0.05, ** P <0.01, *** P <0.001, **** P <0.0001.

Article Snippet: The final quantification of GFP+/DAPI+, CC-1+/DAPI+, GFP+/CC-1+/DAPI+ and CTIP2+/DAPI+ cells was done using Imaris 7.5.1 ( www.bitplane.com ).

Techniques: In Vivo, Magnetic Resonance Imaging, Staining, BrdU Incorporation Assay, End Labeling, TUNEL Assay, Two Tailed Test

Journal: bioRxiv

Article Title: Imp1 acts as a dosage- and stage-dependent temporal rheostat orchestrating radial glial fate transitions and cortical morphogenesis

doi: 10.1101/2025.11.18.688993

Figure Lengend Snippet: (A,D,G) Representative images of control, continuous Imp1 overexpression, and T1 Imp1 conditions showing TEMPO reporters, Cux1/Ctip2 immunostaining and overlays. Boxed regions: Ctip2+ TEMPO neurons (dashed) or double-positive Cux1+/Ctip2+ TEMPO cells (solid). (B,E,H) High magnification images of boxed regions highlight CFP-/RFP-labeled neurons in layers V-VI colocalizing with Ctip2 (outlined arrowheads) or double-positive for both markers (solid arrowheads). (C,F,I) Quantification of marker expression in CFP+ and RFP+ neurons residing in layers V-VI. Following continuous or T1 Imp1 overexpression, neurons in deep layer maintain appropriate deep-layer molecular identities (predominantly Ctip2+), demonstrating that laminar distribution reflects bona fide fate specification changes rather than mislocalization. (C) In control conditions, CFP+: Ctip2 (78.31% ± 13.82%), Cux1 (2.93% ± 2.11%), double-negative (18.76% ± 11.73%). RFP+: Ctip2 (50.35% ± 17.01%), Cux1 (1.85% ± 1.85%), double-negative (46.76% ± 17.20%), double-positive (1.04% ± 1.04%). (F) Following continuous Imp1 overexpression, CFP+: Ctip2+ (71.18% ± 3.06%), Cux1+ (7.38% ± 4.93%), double-negative (16.06% ± 1.93%), double-positive (5.38% ± 1.80%). RFP+: Ctip2+ (58.92% ± 7.18%), Cux1+ (5.84% ± 3.01%), double-negative (5.10% ± 3.12%), double-positive (30.14% ± 11.98%). (I) In T1 Imp1 overexpression, CFP+: Ctip2+ (47.26% ± 4.88%), Cux1+ (14.63% ± 3.76%), double-negative (36.41% ± 5.64%), double-positive (1.68% ± 0.57%). RFP+: Ctip2+ (47.38% ± 13.91%), Cux1+ (9.17% ± 4.68%), double-negative (26.86% ± 5.03%), double-positive (16.59% ± 10.02%). Dashed lines: upper (II-IV), lower cortical layers (V-VI) and subplate zone (SPZ). Scale bars: (A,D,G) 100 µm and (B,E,H) 20 µm. Data show mean±SEM. Statistics: two-tailed unpaired Welch’s t-test (*P < 0.05, **P < 0.01, *** P < 0.001).

Article Snippet: Primary antibodies were applied overnight to amplify TEMPO signals or detect fate markers at 4°C: mouse anti-V5 (1:650, Thermo Fisher R96025) to detect CFP+ cells, rat anti-mCherry (1:500, Thermo Fisher M11217) or chicken anti-mCherry (1:500, AvesLabs MCHERRY AB_2910557) to detect RFP+ cells, rat anti-Ctip2 (1:100, Abcam [25B6] ab18465) to detect Ctip2+ cells, and rabbit anti-Cux1 (1:50, Proteintech 11733-1-AP) to detect Cux1+ cells.

Techniques: Control, Over Expression, Immunostaining, Labeling, Marker, Expressing, Two Tailed Test

Review

Structured Review

Images

1) Product Images from "Imp1 acts as a dosage- and stage-dependent temporal rheostat orchestrating radial glial fate transitions and cortical morphogenesis"

Similar Products

Image Search Results